8-K: FDA Extends Review of Rocket Pharma's Gene Therapy for LAD-I, PDUFA Date Now June 30

The FDA has extended the review period for Rocket Pharmaceuticals' KRESLADI gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I) by three months, with a new PDUFA date of June 30, 2024.

Summary

• The U.S. Food and Drug Administration (FDA) has extended the Priority Review period for Rocket Pharmaceuticals' Biologics License Application (BLA) for KRESLADI (marnetegragene autotemcel) by three months.
• The new Prescription Drug User Fee Act (PDUFA) date is now June 30, 2024.
• The extension is to allow the FDA additional time to review clarifying Chemistry, Manufacturing, and Controls (CMC) information submitted by Rocket in response to FDA information requests.
• The FDA has confirmed that an advisory committee meeting is not needed for this application.
• Positive top-line data from the global Phase 1/2 study of KRESLADI showed 100% overall survival at 12 months post-infusion for all nine LAD-I patients with 12 to 24 months of follow-up.
• The study also demonstrated significant decreases in the incidence of infections, resolution of skin lesions, and restoration of wound repair capabilities.
• All primary and secondary endpoints were met, and KRESLADI was well tolerated with no treatment-related serious adverse events.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The positive clinical data is encouraging, but the delay in the PDUFA date is a setback. Overall, the sentiment is cautiously optimistic.

Positives

• The FDA has confirmed that an advisory committee meeting is not needed, which can streamline the approval process.
• Clinical trial data showed 100% overall survival at 12 months post-infusion for all nine LAD-I patients.
• KRESLADI was very well tolerated in all patients with no treatment related serious adverse events.
• The therapy demonstrated significant reductions in infections and improvements in skin lesions and wound repair.

Negatives

• The FDA has extended the review period by three months, which delays the potential approval and launch of KRESLADI.

Risks

• The extended review period could lead to further delays in the approval process.
• There is a risk that the FDA may require additional information or studies before approving the therapy.
• The company is dependent on third parties for development, manufacture, marketing, sales and distribution of product candidates.
• The company is subject to risks related to litigation and unexpected expenditures.

Future Outlook

Rocket Pharmaceuticals remains confident and focused on making KRESLADI available for patients as quickly as possible and looks forward to continuing close collaboration with the FDA.

Management Comments

• We look forward to continuing our close collaboration with the FDA and together share a deep sense of responsibility in the rigorous process required to bring novel, potentially curative gene therapies, like KRESLADITM to patients who need them most, said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma.
• We remain confident and focused on making this therapy available for patients as quickly as possible.

Industry Context

This announcement is relevant to the gene therapy sector, particularly for companies developing treatments for rare diseases. The delay highlights the complexities of regulatory approvals for novel therapies and the importance of robust CMC data.

Comparison to Industry Standards

• The 100% survival rate at 12 months in the KRESLADI trial is a very positive result, especially when compared to the natural history of LAD-I, where survival beyond childhood is rare without a successful bone marrow transplant.
• The lack of treatment-related serious adverse events is also a positive outcome, as gene therapies can sometimes have safety concerns.
• The delay in the PDUFA date is not uncommon in the biotech industry, as the FDA often requires additional information to ensure the safety and efficacy of new therapies.
• Other companies developing gene therapies for rare diseases, such as Bluebird Bio and Orchard Therapeutics, have also experienced regulatory delays and challenges.

Stakeholder Impact

• The delay in the PDUFA date may disappoint investors, potentially impacting the company's stock price.
• Patients and families affected by LAD-I will have to wait longer for a potential treatment option.
• The positive clinical data and the lack of serious adverse events are encouraging for patients and the medical community.

Next Steps

• Rocket Pharmaceuticals will continue to work with the FDA to address the CMC information requests.
• The company will await the FDA's decision on the BLA by the new PDUFA date of June 30, 2024.

Key Dates

Keywords

KRESLADI, Leukocyte Adhesion Deficiency-I, LAD-I, Gene Therapy, FDA, Priority Review, Biologics License Application, PDUFA, Rare Disease, Rocket Pharmaceuticals